The Tesamorelin & Ipamorelin peptide blend is a mixture of peptide compounds that have been studied for their possible interaction with certain receptors in the cells of the pituitary gland. These receptors include the growth-hormone secretagogue (GHS) receptors and growth hormone-releasing hormone (GHRH) receptors, which are associated with the release of growth hormone (hGH).
Tesamorelin, which is a synthetic peptide, is believed by researchers to act as an analog of growth hormone-releasing hormone through binding to GHRH receptors.[1] Tesamorelin consists of an amino acid chain with 44 amino acids, including a specific sequence similar to GHRH. Additionally, Tesamorelin has been modified in an effort to support its resistance to enzymatic degradation. As an example, the C-terminus of the synthetically developed Tesamorelin has been modified with a trans-3-hexenoic acid group. This modification, known as an omega-amino acid modification, may help improve the peptide’s resistance to enzymatic degradation.
Tesamorelin also has an acetyl group (CH₃CO-) attached to its N-terminus, which may potentially enhance the stability and bioactivity of the peptide. As a result, the peptide is also known as N-(trans-3-hexenoyl)-[Tyr1]hGRF(1–44)NH2 acetate.[2] By interacting with GHRH receptors in the pituitary and hypothalamus, Tesamorelin may trigger the release of hGH from pituitary cells.
Similarly, Ipamorelin is also a synthetic peptide that interacts with pituitary cells and may stimulate the synthesis and release of hGH. Its proposed mechanism of action involves interaction with GHS receptors, also known as ghrelin receptors, which are found in the pituitary and hypothalamus.[3] By activating these receptors, Ipamorelin may mimic the actions of ghrelin on the pituitary gland, potentially leading to the release of growth hormone from pituitary cells.
Reviews
There are no reviews yet.